Subscribe to be notified for updates: RSS Feed


Recent RNS

Operational and financial highlights for the first half of 2016 with commentary from Chairman of the Board, Jose Barella, and CEO, Bruno Jactel. Read more…

The Company’s trading performance in the first half continues the upward trend from prior periods. Unit sales of Vamousse were in line with expectations. The roll-out of PureScience in the first half was slower than anticipated mainly due to the time of completing the field trials. Read more

Read All RNS
Featured Video
CEO, Bruno Jactel Discusses Vamousse And The Group’s Very Good First Half